


Reference Data

(Consolidated Financial Results for Q3 FY2018)



Daiichi-Sankyo

January 31, 2019

Daiichi Sankyo Co., Ltd.

<https://www.daiichisankyo.com>

Contents

1.	Consolidated Statement of Profit or Loss	P1
2.	Revenue of Global Products	P2
3.	Revenue by Business Units and Products	P3
4.	Consolidated Statement of Financial Position	P6
5.	Consolidated Statement of Cash Flows	P8
6.	Number of Employees	P9
7.	Capital Expenditure, Depreciation and Amortization	P9
8.	Summary of Product Outlines	P10
9.	Quarterly Data	P11
10.	Historical Data	P16
11.	Major R&D Pipeline (Innovative pharmaceuticals)	P20

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2017 Q3 YTD		FY2018 Q3 YTD					FY2018			
	to revenue	Results	to revenue	Results	(vs. Forecast (%))	YoY	YoY (%)	to revenue	Forecast	YoY	YoY (%)
Revenue	100.0%	741.0	100.0%	703.1	(77.3%)	-38.0	-5.1%	100.0%	910.0	-50.2	-5.2%
Cost of sales	34.5%	255.5	37.7%	264.9	(80.3%)	9.5	+3.7%	36.3%	330.0	-16.0	-4.6%
(excl. Special items)	35.3%	261.5	37.7%	264.9		3.4	+1.3%				
(Special items)	-0.8%	-6.1	-	-		6.1	-				
Gross Profit	65.5%	485.6	62.3%	438.2	(75.5%)	-47.4	-9.8%	63.7%	580.0	-34.2	-5.6%
SG&A expenses	29.2%	216.7	28.2%	198.5	(69.2%)	-18.2	-8.4%	31.5%	287.0	-14.8	-4.9%
(excl. Special items)	29.2%	216.7	28.7%	202.0		-14.8	-6.8%				
(Special items)	-	-	-0.5%	-3.5		-3.5	-				
R&D expenses	23.7%	175.6	20.3%	142.6	(66.3%)	-33.0	-18.8%	23.6%	215.0	-21.0	-8.9%
(excl. Special items)	19.6%	145.4	20.3%	142.6		-2.9	-2.0%				
(Special items)	4.1%	30.2	-	-		-30.2	-				
Operating Profit	12.6%	93.2	13.8%	97.1	(124.5%)	3.9	+4.1%	8.6%	78.0	1.7	+2.3%
(Operating Profit before Special items)	15.8%	117.3	13.3%	93.6		-23.7	-20.2%				
Financial income/expenses		4.1		0.5		-3.6					
Share of profit or loss of investments accounted for using the equity method		0.4		0.3		-0.1					
Profit before tax	13.2%	97.7	13.9%	98.0	(125.6%)	0.2	+0.2%	8.6%	78.0	-3.0	-3.7%
Income taxes		25.6		19.1		-6.5	-25.2%				
Profit for the year	9.7%	72.1	11.2%	78.8	(143.3%)	6.7	+9.3%	6.0%	55.0	-4.8	-8.0%
Profit attributable to owners of the Company	9.8%	72.6	11.2%	78.8	(143.3%)	6.2	+8.5%	6.0%	55.0	-5.3	-8.8%
Tax rate		26.2%		19.5%							
Overseas sales ratio		35.4%		35.7%							
Currency Rate (Average)											
USD/JPY		111.71		111.15							
EUR/JPY		128.53		129.49							

	FY2017 Q3 YTD	FY2018 Q3 YTD
Cost of Sales	Gain on sales of fixed assets -6.1	
SG&A expenses		Gain on sales of fixed assets -3.5
R&D expenses	Impairment loss (Intangible) 30.2	
Total	24.1	-3.5

	Forecast	
	USD	EUR
Revenue	1.3 JPY Bn	0.6 JPY Bn
Operating Profit	-0.4 JPY Bn	0.1 JPY Bn

*This report is not subject to audit procedures.

*Special items : Items having a transitory and material impact on operating profit are defined as "Special items".

Specifically, gains and losses related to: sale of fixed assets, restructuring, impairment, litigation, etc. amounting to 1 billion JPY or more are defined as "Special items".

2. Revenue of Global Products

JPY Bn	FY2017 Q3 YTD		FY2018 Q3 YTD				FY2018		
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Edoxaban anticoagulant	56.6		87.4	(78.7%)	30.8	+54.4%	111.0	33.9	+44.0%
Lixiana (JPN)	34.7		49.3	(82.1%)	14.6	+42.1%	60.0	14.7	+32.3%
Savaysa (US)	1.6		1.6	(81.4%)	0.0	+0.9%	2.0	-0.2	-7.8%
Lixiana (EU)	18.5		33.3	(74.1%)	14.9	+80.4%	45.0	18.0	+66.7%
Other subsidiaries	1.8		3.2	(79.1%)	1.3	+71.7%	4.0	1.4	+54.9%
Olmesartan antihypertensive agent	120.6		80.9	(83.4%)	-39.7	-32.9%	97.0	-52.7	-35.2%
Olmotec (JPN)	40.5		11.9	(85.3%)	-28.5	-70.5%	14.0	-30.6	-68.6%
Rezaltas (JPN)	13.1		12.2	(86.9%)	-1.0	-7.5%	14.0	-2.8	-16.5%
Olmesartan (US)	17.4		7.9	(88.0%)	-9.4	-54.3%	9.0	-12.3	-57.8%
Olmesartan (EU)	25.5		21.0	(91.3%)	-4.5	-17.6%	23.0	-10.5	-31.4%
Other subsidiaries, export, etc	24.2		27.8	(75.2%)	3.7	+15.2%	37.0	3.5	+10.6%
Prasugrel antiplatelet agent	27.0		18.8	-	-8.2	-30.3%	not disclosed	-	-
Effient alliance revenue (US)	10.1		2.4	-	-7.7	-75.9%	not disclosed	-	-
Efient (EU)	6.0		4.6	(65.8%)	-1.4	-22.8%	7.0	-1.0	-12.7%
Efient (JPN)	9.9		10.9	(72.5%)	0.9	+9.4%	15.0	2.2	+16.9%
Other subsidiaries, export, etc	1.0		0.9	-	-0.1	-7.6%	not disclosed	-	-

3. Revenue by Business Units and Products (1)

JPY Bn	FY2017 Q3 YTD		FY2018 Q3 YTD				FY2018		
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Japan	418.1		395.7	(77.1%)	-22.4	-5.4%	513.0	-27.0	-5.0%
Nexium	70.0		61.0	(80.2%)	-9.0	-12.9%	76.0	-10.5	-12.2%
Lixiana	34.7		49.3	(82.1%)	14.6	+42.1%	60.0	14.7	+32.3%
Memary	38.1		39.5	(77.5%)	1.4	+3.8%	51.0	2.4	+5.0%
Loxonin	29.0		24.3	(78.3%)	-4.7	-16.3%	31.0	-5.5	-15.0%
Pralia	17.3		21.0	(77.7%)	3.7	+21.7%	27.0	3.8	+16.5%
Tenelia	20.9		19.9	(73.7%)	-1.0	-4.7%	27.0	0.7	+2.7%
Inavir	9.3		4.5	(23.5%)	-4.8	-51.8%	19.0	-6.3	-24.8%
Olmotec	40.5		11.9	(85.3%)	-28.5	-70.5%	14.0	-30.6	-68.6%
Ranmark	11.7		12.7	(79.4%)	1.0	+8.4%	16.0	0.6	+3.9%
Efient	9.9		10.9	(72.5%)	0.9	+9.4%	15.0	2.2	+16.9%
Rezaltas	13.1		12.2	(86.9%)	-1.0	-7.5%	14.0	-2.8	-16.5%
Urief	8.7		8.2	(82.0%)	-0.5	-5.5%	10.0	-1.1	-10.1%
Omnipaque	11.0		9.5	(79.6%)	-1.4	-12.9%	12.0	-2.0	-14.1%
Daiichi Sankyo Espha products	34.3		42.4	-	8.1	+23.5%	not disclosed	-	-
Vaccines business	34.5		34.5	-	0.0	+0.1%	not disclosed	-	-
Daiichi Sankyo Healthcare (OTC)	56.6		52.9	(76.7%)	-3.6	-6.4%	69.0	-3.9	-5.4%

3. Revenue by Business Units and Products (2)

JPY Bn	FY2017 Q3 YTD		FY2018 Q3 YTD				FY2018		
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Daiichi Sankyo, Inc. (US)	64.1		28.6	(92.2%)	-35.5	-55.4%	31.0	-43.8	-58.5%
Olmesartan antihypertensive agent	17.4		7.9	(88.0%)	-9.4	-54.3%	9.0	-12.3	-57.8%
Welchol hypercholesterolemia treatment/ type 2 diabetes mellitus treatment	29.3		11.0	(109.5%)	-18.3	-62.6%	10.0	-23.9	-70.5%
Effient antiplatelet agent	10.1		2.4	-	-7.7	-75.9%	not disclosed	-	-
Savaysa anticoagulant	1.6		1.6	(81.4%)	0.0	+0.9%	2.0	-0.2	-7.8%
Movantik opioid-induced constipation treatment	3.7		3.3	-	-0.5	-12.1%	not disclosed	-	-
American Regent, Inc.* (US)	79.9		90.1	(79.8%)	10.2	+12.8%	113.0	7.6	+7.2%
Venofer treatment for iron deficiency anemia	24.0		24.1	(83.2%)	0.1	+0.4%	29.0	-2.0	-6.3%
Injectafer treatment for iron deficiency anemia	25.2		33.7	(82.2%)	8.5	+33.7%	41.0	6.7	+19.4%
* Formerly, Luitpold Pharmaceuticals, Inc.									
Daiichi Sankyo Europe GmbH	58.2		66.0	(77.7%)	7.8	+13.4%	85.0	5.6	+7.0%
Olmesartan antihypertensive agent	25.5		21.0	(91.3%)	-4.5	-17.6%	23.0	-10.5	-31.4%
Efient antiplatelet agent	6.0		4.6	(65.8%)	-1.4	-22.8%	7.0	-1.0	-12.7%
Lixiana anticoagulant	18.5		33.3	(74.1%)	14.9	+80.4%	45.0	18.0	+66.7%
Asia, South and Central America (ASCA)	58.7		63.1	(70.1%)	4.4	+7.6%	90.0	9.6	+12.0%
Daiichi Sankyo China	25.2		26.9	-	1.7	+6.9%	not disclosed	-	-
Daiichi Sankyo Taiwan	4.8		5.3	-	0.5	+9.9%	not disclosed	-	-
Daiichi Sankyo Korea	8.6		11.2	-	2.6	+30.1%	not disclosed	-	-
Daiichi Sankyo Thailand	2.1		2.4	-	0.3	+16.7%	not disclosed	-	-
Daiichi Sankyo Brasil Farmacêutica	8.1		7.8	-	-0.3	-3.4%	not disclosed	-	-

3. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

		FY2017 Q3 YTD				FY2018 Q3 YTD				FY2018		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)			
USD Mn												
Daiichi Sankyo, Inc. (US)		573	257	(91.4%)	-316	-55.1%	281	-393	-58.3%			
Olmesartan	antihypertensive agent	155	71	(87.2%)	-84	-54.1%	82	-111	-57.5%			
Welchol	hypercholesterolemia treatment/ type 2 diabetes mellitus treatment	262	99	(108.5%)	-163	-62.4%	91	-215	-70.3%			
Effient	antiplatelet agent	91	22	-	-69	-75.8%	not disclosed	-	-			
Savaysa	anticoagulant	14	15	(80.7%)	0	+1.4%	18	-1	-7.2%			
Movantik	opioid-induced constipation treatment	33	29	-	-4	-11.7%	not disclosed	-	-			
USD Mn												
American Regent, Inc.* (US)		715	811	(79.0%)	96	+13.4%	1,026	75	+7.9%			
Venofer	treatment for iron deficiency anemia	215	217	(82.4%)	2	+0.9%	263	-16	-5.7%			
Injectafer	treatment for iron deficiency anemia	226	303	(81.4%)	77	+34.3%	372	63	+20.2%			
* Formerly, Luitpold Pharmaceuticals, Inc.												
EUR Mn												
Daiichi Sankyo Europe GmbH		453	510	(77.9%)	57	+12.6%	654	42	+6.8%			
Olmesartan	antihypertensive agent	198	162	(91.6%)	-36	-18.2%	177	-81	-31.5%			
Efient	antiplatelet agent	46	36	(66.0%)	-11	-23.3%	54	-8	-12.8%			
Lixiana	anticoagulant	144	258	(74.3%)	114	+79.1%	346	138	+66.4%			

4. Consolidated Statement of Financial Position

<Assets>

JPY Bn

	Mar. 2018	Dec. 2018	vs. Mar. 2018
Assets			
Current assets			
Cash and cash equivalents	357.7	239.2	-118.5
Trade and other receivables	231.5	305.7	74.2
Other financial assets	429.4	490.4	61.0
Inventories	172.6	177.6	5.0
Other current assets	10.3	13.1	2.7
Total current assets	1,201.5	1,225.9	24.4
Non-current assets			
Property, plant and equipment	217.9	225.7	7.8
Goodwill	75.5	77.8	2.3
Intangible assets	173.5	170.4	-3.2
Investments accounted for using the equity method	1.7	2.4	0.7
Other financial assets	179.2	118.7	-60.5
Deferred tax assets	40.3	66.6	26.2
Other non-current assets	8.0	6.2	-1.9
Total non-current assets	696.2	667.7	-28.5
Total assets	1,897.8	1,893.6	-4.2

Insurance credit for olmesartan litigation settlement
(Transfer from Non-current assets "Other financial assets")

Acquisition +27.1, Depreciation -19.3

Acquisition +7.6, Amortization -14.9, Forex impact +4.2

Insurance credit for olmesartan litigation settlement
(Transfer to Current assets "Trade and other receivables")

DTA related to prior year's restructuring +12.6

*	Liquidity on hand	786.5	729.3	-57.1
	Debt with interest	282.1	262.0	-20.1
	Net Cash	504.4	467.4	-37.0

<Liabilities and equity>

JPY Bn

	Mar. 2018	Dec. 2018	vs. Mar. 2018	
Liabilities				
Current liabilities				
Trade and other payables	226.2	260.2	34.0	Provisions for olmesartan litigation settlement (Transfer from Non-current liabilities "Provisions")
Bonds and borrowings	20.0	40.0	20.0	2nd Unsecured Corporate Bond +40.0 (Transfer from Non-current liabilities "Bonds and borrowings"), Borrowings repayment -20.0
Other financial liabilities	0.5	0.5	-0.1	
Income taxes payable	64.6	8.8	-55.8	Reversal of tax liability related to prior year's restructuring -53.8
Provisions	34.0	6.8	-27.2	
Other current liabilities	7.8	14.5	6.7	
Total current liabilities	353.1	330.7	-22.4	
Non-current liabilities				
Bonds and borrowings	260.6	220.6	-40.0	2nd Unsecured Corporate Bond -40.0 (Transfer to Current liabilities "Trade and other payables")
Other financial liabilities	8.2	7.3	-0.8	
Post employment benefit liabilities	10.5	9.9	-0.7	
Provisions	48.8	10.4	-38.3	Provisions for olmesartan litigation settlement (Transfer to Current liabilities "Trade and other payables")
Deferred tax liabilities	18.7	19.5	0.8	
Other non-current liabilities	64.9	60.2	-4.7	
Total non-current liabilities	411.6	327.9	-83.7	
Total liabilities	764.7	658.6	-106.1	
Equity				
Equity attributable to owners of the Company				
Share capital	50.0	50.0	-	
Capital surplus	94.6	94.6	-	
Treasury shares	-163.5	-163.1	0.5	
Other components of equity	120.5	116.5	-4.0	
Retained earnings	1,031.4	1,136.9	105.5	Profit for the period +78.8, Payment of dividends -45.3, Increase due to reversal of tax liability related to prior year's restructuring +66.4
Total equity attributable to owners of the Company	1,133.0	1,235.0	102.0	
Non-controlling interests				
Non-controlling interests	0.1	0.1	0.0	
Total equity	1,133.0	1,235.0	102.0	
Total liabilities and equity	1,897.8	1,893.6	-4.2	

5. Consolidated Statement of Cash Flows

JPY Bn

	FY2017 Q3 YTD	FY2018 Q3 YTD	YoY
Cash flows from operating activities			
Profit before tax	97.7	98.0	0.2
Depreciation and amortization	33.5	34.3	0.8
(Increase) decrease in receivables and payables	-71.5	-65.4	6.1
Others, net	4.0	-16.3	-20.3
Income taxes paid	-19.9	-29.9	-10.0
Net cash flows from operating activities	43.8	20.7	-23.2
Cash flows from investing activities			
Net (increase) decrease in time deposits and securities	77.8	-57.3	-135.1
(Acquisition of) proceeds from sales of fixed assets	-25.6	-34.6	-9.0
Net (increase) decrease in investment securities	3.9	11.9	8.1
Others, net	8.4	4.6	-3.8
Net cash flows from investing activities	64.5	-75.4	-139.9
Cash flows from financing activities			
Net (increase) decrease in borrowings	-	-20.0	-20.0
Purchase of treasury shares	-20.1	-0.0	20.0
Dividends paid	-46.5	-45.4	1.1
Others, net	-4.7	-0.7	4.0
Net cash flows from financing activities	-71.2	-66.1	5.1
Net increase (decrease) in cash and cash equivalents	37.1	-120.9	-158.0
Cash and cash equivalents at the beginning of the period	246.1	357.7	111.7
Effect of exchange rate changes on cash and cash equivalents	5.4	2.3	-3.1
Cash and cash equivalents at the end of the period	288.6	239.2	-49.5
* Free cash flows (Cash flows from operating activities and investing activities)	108.3	-54.8	-163.1

6. Number of Employees

	Dec. 2017	Mar. 2018	Dec. 2018
	Results	Results	Results
Consolidated	14,818	14,446	14,858
Japan	8,822	8,765	8,893
North America	2,483	2,191	2,190
Europe	1,563	1,582	1,757
Others	1,950	1,908	2,018

7. Capital Expenditure, Depreciation and Amortization

	JPY Bn	FY2017 Q3 YTD	FY2017	FY2018 Q3 YTD	FY2018
		Results	Results	Results	Forecast
Capital expenditure		18.2	26.9	26.3	41.5
Depreciation and amortization		33.5	46.7	34.3	47.0
Property, plant and equipment		19.1	27.4	19.4	-
Intangible assets		14.4	19.3	14.9	-

8. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance	Type of Alliance
Japan						
Nexium	esomeprazole	ulcer treatment	2011	AstraZeneca	AstraZeneca	Co-promotion (DS: Sales)
Lixiana	edoxaban	anticoagulant	2011	Daiichi Sankyo		
Memary	memantine	Alzheimer's disease treatment	2011	Merz		
Loxonin			1986	Daiichi Sankyo		
Loxonin Poulrice	loxoprofen	anti-inflammatory analgesic	2006	Lead Chemical		
Loxonin Tape			2008	Lead Chemical		
Loxonin Gel			2010	Daiichi Sankyo		
Pralia	denosumab	treatment for osteoporosis/ inhibitor of the progression of bone erosion associated with rheumatoid arthritis	2013	Amgen		
Tenelia	teneligliptin	type 2 diabetes mellitus treatment	2012	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Inavir	laninamivir	anti-influenza treatment	2010	Daiichi Sankyo		
Olmetec	olmesartan	antihypertensive agent	2004	Daiichi Sankyo		
Ranmark	denosumab	treatment for bone complications caused by bone metastases from tumors	2012	Amgen		
Efient	prasugrel	antiplatelet agent	2014	Daiichi Sankyo Ube Industries		
Rezaltas	olmesartan / azelnidipine	antihypertensive agent	2010	Daiichi Sankyo		
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei	Co-marketing
Omnipaque	iohexol	contrast medium	1987	GE Healthcare		
Daiichi Sankyo, Inc. (US)						
Olmesartan						
Benicar	olmesartan		2002			
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive agent	2003	Daiichi Sankyo		
Azor	olmesartan / amlodipine		2007			
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010			
Welchol	colesevelam	hypercholesterolemia treatment/ type 2 diabetes mellitus treatment	2000	Genzyme		
Effient	prasugrel	antiplatelet agent	2009	Daiichi Sankyo Ube Industries	Lilly	Co-promotion (DS: Co-pro revenue)
Savaysa	edoxaban	anticoagulant	2015	Daiichi Sankyo		
Movantik	naloxegol	opioid-induced constipation treatment	2015	Nektar AstraZeneca	AstraZeneca	Co-promotion (DS: Co-pro revenue)
American Regent, Inc.* (US)						
Venofer	iron sucrose injection	treatment for iron deficiency anemia	2000	Vifor Pharma	Fresenius	Co-marketing
Injectafer	ferric carboxymaltose injection	treatment for iron deficiency anemia	2013	Vifor Pharma	Daiichi Sankyo, Inc.	Promotion (Daiichi Sankyo, Inc.)
* Formerly, Luitpold Pharmaceuticals, Inc.						
Daiichi Sankyo Europe GmbH						
Olmesartan						
Olmetec	olmesartan		2002			
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive agent	2005	Daiichi Sankyo	Menarini Pfizer	Co-marketing
Sevikar	olmesartan / amlodipine		2009			
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010			
Efient	prasugrel	antiplatelet agent	2009	Daiichi Sankyo Ube Industries		
Lixiana	edoxaban	anticoagulant	2015	Daiichi Sankyo	Merck (MSD)	Co-marketing

<9. Quarterly Data>

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2017	FY2017	FY2017	FY2017	FY2017				FY2018	FY2018	FY2018	FY2018	FY2018	
	Q1	Q2	Q3	Q4	to revenue	Results	YoY	YoY (%)	Q1	Q2	Q3	Q4	to revenue	Results
	Results	Results	Results	Results					Results	Results	Results	Results		
Revenue	239.1	230.3	271.7	219.1	100.0%	960.2	5.1	+0.5%	225.7	221.1	256.2		100.0%	703.1
Cost of sales	80.1	77.0	98.4	90.6	36.0%	346.0	-3.4	-1.0%	84.7	81.9	98.3		37.7%	264.9
(excl. Special items)	80.1	83.1	98.4	85.5	36.1%	347.0	21.9	+6.7%	84.7	81.9	98.3		37.7%	264.9
(Special items)	-	-6.1	-	5.1	-0.1%	-1.0	-25.2	-	-	-	-		-	-
Gross Profit	159.0	153.3	173.3	128.6	64.0%	614.2	8.4	+1.4%	141.0	139.2	158.0		62.3%	438.2
SG&A expenses	70.8	69.2	76.7	85.1	31.4%	301.8	-0.6	-0.2%	65.6	63.0	70.0		28.2%	198.5
(excl. Special items)	70.8	69.2	76.7	80.6	31.0%	297.4	6.6	+2.3%	65.6	66.4	70.0		28.7%	202.0
(Special items)	-	-	-	4.5	0.5%	4.5	-7.2	-	-	-3.5	-		-0.5%	-3.5
R&D expenses	48.0	75.6	52.0	60.4	24.6%	236.0	21.7	+10.1%	45.5	48.2	48.9		20.3%	142.6
(excl. Special items)	48.0	45.4	52.0	60.4	21.4%	205.9	-4.0	-1.9%	45.5	48.2	48.9		20.3%	142.6
(Special items)	-	30.2	-	-	3.1%	30.2	25.7	-	-	-	-		-	-
Operating Profit	40.3	8.5	44.5	-16.9	7.9%	76.3	-12.6	-14.2%	29.9	28.1	39.1		13.8%	97.1
(Operating Profit before Special items)	40.3	32.6	44.5	-7.4	11.4%	109.9	-19.4	-15.0%	29.9	24.6	39.1		13.3%	93.6
Financial income/expenses	2.1	0.5	1.5	0.3		4.4	5.7		-0.2	1.0	-0.3			0.5
Share of profit or loss of investments accounted for using the equity method	-0.1	-0.1	0.6	-0.1		0.3	0.2		-0.1	-0.0	0.5			0.3
Profit before tax	42.2	9.0	46.5	-16.7	8.4%	81.0	-6.8	-7.7%	29.6	29.0	39.3		13.9%	98.0
Income taxes	13.4	4.0	8.2	-4.4		21.2	-19.1	-47.4%	5.7	8.9	4.5			19.1
Profit for the year	28.8	4.9	38.4	-12.3	6.2%	59.8	12.3	+26.0%	24.0	20.1	34.8		11.2%	78.8
Profit attributable to owners of the Company	29.2	5.1	38.3	-12.3	6.3%	60.3	6.8	+12.7%	24.0	20.1	34.8		11.2%	78.8
Tax rate	31.8%	44.8%	17.5%	26.3%		26.2%			19.2%	30.8%	11.5%			19.5%
Overseas sales ratio	37.6%	35.5%	33.2%	36.4%		35.6%			36.5%	37.5%	33.4%			35.7%
Currency Rate (YTD Average)														
USD/JPY	111.10	111.07	111.71	110.86		110.86			109.07	110.27	111.15			111.15
EUR/JPY	122.19	126.29	128.53	129.70		129.70			130.06	129.84	129.49			129.49

<9. Quarterly Data>

2. Revenue of Global Products

JPY Bn	FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2017			FY2018 Q1	FY2018 Q2	FY2018 Q3	FY2018 Q4	FY2018
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
Edoxaban	15.3	17.6	23.7	20.5	77.1	39.8	+106.5%	25.8	28.3	33.3		87.4
Lixiana (JPN)	9.4	10.3	15.0	10.7	45.3	20.3	+81.4%	14.7	15.4	19.1		49.3
Savaysa (US)	0.5	0.5	0.6	0.6	2.2	0.3	+15.6%	0.4	0.7	0.5		1.6
Lixiana (EU)	4.9	6.1	7.5	8.5	27.0	17.3	+179.1%	9.7	11.1	12.5		33.3
Other subsidiaries	0.6	0.6	0.7	0.7	2.6	1.8	+230.3%	1.0	1.2	1.0		3.2
Olmesartan	42.8	40.0	37.8	29.1	149.7	-68.3	-31.3%	28.5	25.0	27.4		80.9
Olmotec (JPN)	16.8	15.1	8.6	4.1	44.6	-24.8	-35.8%	4.2	3.7	4.1		11.9
Rezaltas (JPN)	4.5	4.1	4.6	3.6	16.8	-0.8	-4.4%	4.1	3.7	4.4		12.2
Olmesartan (US)	6.8	3.5	7.0	4.0	21.3	-45.0	-67.8%	3.2	2.7	2.1		7.9
Olmesartan (EU)	9.0	9.0	7.5	8.0	33.5	-9.7	-22.4%	8.2	6.2	6.6		21.0
Other subsidiaries, export, etc	5.8	8.3	10.0	9.3	33.5	12.0	+55.6%	9.0	8.7	10.2		27.8
Prasugrel	11.5	7.2	8.2	5.8	32.8	-8.8	-21.1%	6.4	7.1	5.3		18.8
Effient alliance revenue (US)	6.1	1.9	2.2	0.5	10.7	-11.5	-52.0%	0.6	2.1	-0.3		2.4
Efient (EU)	1.9	2.0	2.1	2.0	8.0	0.1	+0.8%	1.9	1.4	1.3		4.6
Efient (JPN)	3.3	3.1	3.6	2.9	12.8	2.4	+23.2%	3.6	3.4	3.9		10.9
Other subsidiaries, export, etc	0.2	0.3	0.4	0.3	1.3	0.3	+27.4%	0.3	0.3	0.3		0.9

3. Revenue by Business Units and Products (1)	FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2017			FY2018 Q1	FY2018 Q2	FY2018 Q3	FY2018 Q4	FY2018
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
JPY Bn												
Japan	130.0	127.6	160.5	121.9	540.0	33.5	+6.6%	123.9	119.8	152.0		395.7
Nexium	22.6	22.1	25.3	16.6	86.5	2.6	+3.0%	19.8	18.8	22.4		61.0
Lixiana	9.4	10.3	15.0	10.7	45.3	20.3	+81.4%	14.7	15.4	19.1		49.3
Memary	12.5	12.0	13.6	10.5	48.6	1.7	+3.6%	12.9	12.3	14.3		39.5
Loxonin	9.6	9.3	10.1	7.4	36.5	-1.0	-2.6%	7.9	7.7	8.7		24.3
Pralia	5.5	5.4	6.4	5.9	23.2	5.2	+29.1%	6.6	6.4	8.0		21.0
Tenelia	7.6	5.6	7.7	5.4	26.3	2.1	+8.8%	6.4	6.2	7.3		19.9
Inavir	0.7	0.4	8.2	16.0	25.3	5.7	+29.2%	0.1	-0.0	4.4		4.5
Olmotec	16.8	15.1	8.6	4.1	44.6	-24.8	-35.8%	4.2	3.7	4.1		11.9
Ranmark	3.8	3.8	4.2	3.7	15.4	1.5	+10.6%	3.9	4.2	4.6		12.7
Efient	3.3	3.1	3.6	2.9	12.8	2.4	+23.2%	3.6	3.4	3.9		10.9
Rezaltas	4.5	4.1	4.6	3.6	16.8	-0.8	-4.4%	4.1	3.7	4.4		12.2
Urief	2.9	2.7	3.1	2.4	11.1	-0.3	-2.7%	2.7	2.5	3.0		8.2
Omnipaque	3.6	3.5	3.9	3.0	14.0	-0.2	-1.6%	3.3	3.0	3.3		9.5
Daiichi Sankyo Espha products	7.2	10.1	17.1	12.4	46.7	26.5	+131.5%	13.7	12.8	15.9		42.4
Vaccines business	7.6	8.6	18.4	7.4	41.9	3.4	+8.8%	8.2	8.6	17.8		34.5
Daiichi Sankyo Healthcare (OTC)	16.8	19.0	20.8	16.3	72.9	6.2	+9.3%	18.4	16.4	18.1		52.9

3. Revenue by Business Units and Products (2)	FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2017			FY2018 Q1	FY2018 Q2	FY2018 Q3	FY2018 Q4	FY2018
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
JPY Bn												
Daiichi Sankyo, Inc. (US)	25.0	17.1	22.0	10.7	74.8	-67.5	-47.5%	11.0	11.0	6.6		28.6
Olmesartan	6.8	3.5	7.0	4.0	21.3	-45.0	-67.8%	3.2	2.7	2.1		7.9
Welchol	10.1	9.6	9.6	4.7	33.9	-11.6	-25.5%	4.9	3.8	2.3		11.0
Effient	6.1	1.9	2.2	0.5	10.7	-11.5	-52.0%	0.6	2.1	-0.3		2.4
Savaysa	0.5	0.5	0.6	0.6	2.2	0.3	+15.6%	0.4	0.7	0.5		1.6
Movantik	1.3	1.2	1.2	0.9	4.7	0.5	+12.3%	0.9	1.2	1.1		3.3
American Regent, Inc. (US)	27.6	24.8	27.6	25.5	105.4	17.3	+19.7%	28.6	29.8	31.7		90.1
Venofer	7.4	7.3	9.3	6.9	31.0	2.5	+8.7%	8.2	8.3	7.6		24.1
Injectafer	8.1	8.1	9.1	9.1	34.3	10.4	+43.3%	11.2	10.8	11.6		33.7
* Formerly, Luitpold Pharmaceuticals, Inc.												
Daiichi Sankyo Europe GmbH	18.5	19.7	19.9	21.3	79.4	8.5	+12.0%	22.2	20.9	23.0		66.0
Olmesartan	9.0	9.0	7.5	8.0	33.5	-9.7	-22.4%	8.2	6.2	6.6		21.0
Efient	1.9	2.0	2.1	2.0	8.0	0.1	+0.8%	1.9	1.4	1.3		4.6
Lixiana	4.9	6.1	7.5	8.5	27.0	17.3	+179.1%	9.7	11.1	12.5		33.3
Asia, South and Central America (ASCA)	19.0	19.6	20.1	21.7	80.4	8.2	+11.4%	19.7	20.4	23.0		63.1
Daiichi Sankyo China	8.3	8.3	8.6	10.1	35.3	1.5	+4.6%	8.4	8.2	10.3		26.9
Daiichi Sankyo Taiwan	1.6	1.6	1.6	1.8	6.6	1.4	+27.5%	1.8	1.7	1.8		5.3
Daiichi Sankyo Korea	2.9	2.7	3.0	3.2	11.8	3.0	+33.5%	3.0	4.2	4.0		11.2
Daiichi Sankyo Thailand	0.6	0.7	0.8	0.8	2.9	0.4	+14.6%	0.8	0.8	0.8		2.4
Daiichi Sankyo Brasil Farmacêutica	2.4	2.4	3.2	2.0	10.1	1.3	+14.6%	2.4	2.5	2.9		7.8

3. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

	FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2017			FY2018 Q1	FY2018 Q2	FY2018 Q3	FY2018 Q4	FY2018
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
USD Mn												
Daiichi Sankyo, Inc. (US)	225	154	195	101	674	-638	-48.6%	101	99	58		257
Olmesartan	61	32	62	37	192	-420	-68.5%	29	24	18		71
Welchol	91	86	85	44	306	-114	-27.1%	45	34	20		99
Effient	55	17	19	6	96	-109	-53.0%	6	19	-3		22
Savaysa	4	5	5	5	20	2	+13.0%	4	6	5		15
Movantik	12	11	11	9	42	4	+9.9%	9	11	10		29
USD Mn												
American Regent, Inc.* (US)	248	223	244	235	951	138	+17.0%	263	267	281		811
Venofer	67	66	82	64	279	17	+6.3%	75	75	67		217
Injectafer	72	73	80	84	310	89	+40.1%	103	97	103		303
* Formerly, Luitpold Pharmaceuticals, Inc.												
EUR Mn												
Daiichi Sankyo Europe GmbH	152	151	150	160	613	15	+2.6%	170	161	178		510
Olmesartan	73	69	56	60	258	-105	-28.9%	63	48	51		162
Efient	16	15	16	15	62	-5	-7.6%	15	10	10		36
Lixiana	40	47	57	64	208	127	+155.7%	75	86	97		258

<10. Historical Data>

1. Revenue of Global Products

	FY2013	FY2014	FY2015	FY2016	FY2017
JPY Bn	Results	Results	Results	Results	Results
Edoxaban	0.4	4.3	15.0	37.3	77.1
Lixiana (JPN)	0.4	3.6	13.0	25.0	45.3
Savaysa (US)	-	0.7	0.4	1.9	2.2
Lixiana (EU)	-	-	1.5	9.7	27.0
Other subsidiaries	-	-	0.0	0.8	2.6
Olmesartan	300.2	293.5	284.1	218.0	149.7
Olmetec (JPN)	79.1	76.3	73.9	69.4	44.6
Rezaltas (JPN)	18.5	18.4	18.2	17.5	16.8
Olmesartan (US)	112.3	106.6	111.6	66.4	21.3
Olmesartan (EU)	65.6	65.2	58.9	43.2	33.5
Other subsidiaries, export, etc	24.7	27.0	21.6	21.5	33.5
Prasugrel	22.3	24.9	32.2	41.6	32.8
Effient alliance revenue (US)	15.4	17.6	20.7	22.2	10.7
Efient (EU)	4.7	4.8	5.4	7.9	8.0
Efient (JPN)	-	0.7	4.9	10.4	12.8
Other subsidiaries, export, etc	2.2	1.9	1.2	1.0	1.3

2. Revenue by Business Units and Products (1)

	FY2013	FY2014	FY2015	FY2016	FY2017
JPY Bn	Results	Results	Results	Results	Results
Japan	486.0	480.5	494.7	506.6	540.0
Nexium	54.2	69.3	82.4	84.0	86.5
Lixiana	0.4	3.6	13.0	25.0	45.3
Memary	33.3	36.8	42.4	46.9	48.6
Loxonin	59.3	49.5	48.1	37.4	36.5
Pralia	3.2	7.3	12.5	18.0	23.2
Tenelia	1.5	7.6	16.5	24.2	26.3
Inavir	13.4	16.6	14.0	19.6	25.3
Olmotec	79.1	76.3	73.9	69.4	44.6
Ranmark	8.1	10.2	12.4	13.9	15.4
Efient	-	0.7	4.9	10.4	12.8
Rezaltas	18.5	18.4	18.2	17.5	16.8
Urief	11.4	11.5	11.8	11.4	11.1
Omnipaque	19.7	17.2	16.9	14.2	14.0
Daiichi Sankyo Espha products	12.5	14.9	18.5	20.2	46.7
Vaccines business	37.5	32.2	36.8	38.5	41.9
Daiichi Sankyo Healthcare (OTC)	48.1	47.8	53.4	66.7	72.9

2. Revenue by Business Units and Products (2)

	FY2013	FY2014	FY2015	FY2016	FY2017
JPY Bn	Results	Results	Results	Results	Results
Daiichi Sankyo, Inc. (US)	171.8	173.0	185.1	142.3	74.8
Olmesartan	112.3	106.6	111.6	66.4	21.3
Welchol	42.3	47.4	48.4	45.5	33.9
Effient	15.4	17.6	20.7	22.2	10.7
Savaysa	-	0.7	0.4	1.9	2.2
Movantik	-	-	2.0	4.2	4.7
American Regent, Inc.* (US)	39.6	57.4	91.0	88.1	105.4
Venofer	24.9	28.6	31.2	28.5	31.0
Injectafer	1.3	7.6	18.6	24.0	34.3
* Formerly, Luitpold Pharmaceuticals, Inc.					
Daiichi Sankyo Europe GmbH	83.9	83.5	77.8	71.0	79.4
Olmesartan	65.6	65.2	58.9	43.2	33.5
Efient	4.7	4.8	5.4	7.9	8.0
Lixiana	-	-	1.5	9.7	27.0
Asia, South and Central America (ASCA)	58.8	67.5	75.3	72.1	80.4
Daiichi Sankyo China	21.2	27.4	34.2	33.8	35.3
Daiichi Sankyo Taiwan	4.5	4.9	5.4	5.2	6.6
Daiichi Sankyo Korea	9.1	8.9	9.3	8.8	11.8
Daiichi Sankyo Thailand	2.5	3.7	4.1	2.5	2.9
Daiichi Sankyo Brasil Farmacêutica	7.5	8.4	8.1	8.8	10.1

2. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

	FY2013	FY2014	FY2015	FY2016	FY2017
	Results	Results	Results	Results	Results
USD Mn					
Daiichi Sankyo, Inc. (US)	1,714	1,574	1,540	1,312	674
Olmesartan	1,120	969	929	612	192
Welchol	422	431	403	420	306
Effient	154	160	173	205	96
Savaysa	-	6	4	17	20
Movantik	-	-	17	38	42
USD Mn					
American Regent, Inc.* (US)	395	522	758	812	951
Venofer	248	260	260	263	279
Injectafer	13	69	155	221	310
* Formerly, Luitpold Pharmaceuticals, Inc.					
EUR Mn					
Daiichi Sankyo Europe GmbH	624	602	587	597	613
Olmesartan	488	470	444	363	258
Effient	35	34	41	67	62
Lixiana	-	-	12	81	208

11. Major R&D Pipeline (Innovative pharmaceuticals)

As of January 2019

◆ Oncology (Late-stage pipeline products)

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
Quizartinib/AC220	FLT3 inhibitor	Acute myeloid leukemia (relapsed/refractory)	JP/US/EU/Asia	Submitted	Oral	-	2019	March 2009: EMA / FDA granted Orphan Drug Designation for the treatment of AML. May 2018: announced top line result August 2018: FDA granted Breakthrough Therapy Designation for relapsed/refractory FLT3-ITD AML September 2018: MHLW granted Orphan Drug Designation for FLT3-mutated AML October 2018: submitted in Japan November 2018: submitted in US and EU
		Acute myeloid leukemia (1st line)	JP/US/EU/Asia	P3		-	2021-	March 2009: EMA / FDA granted Orphan Drug Designation for the treatment of AML. September 2018: MHLW granted Orphan Drug Designation from for FLT3-mutated AML
Kinase inhibitor against a receptor-type tyrosine kinase, FLT3. Therapeutic effect for patients with acute myeloid leukemia harboring FLT3-ITD mutation is expected.								
Pexidartinib/PLX3397	CSF-1R/KIT/FLT3 inhibitor	Tenosynovial giant cell tumor	US/EU	P3	Oral	-	2019	Including pigmented villonodular synovitis November 2015: FDA granted Breakthrough Therapy Designation for tenosynovial giant cell tumor October 2017: announced top line result
		Solid tumors	Asia	P1		-	-	Including TGCT
The molecular-targeted agent to inhibit CSF-1R, KIT and FLT3. This agent is expected to reduce tumor cell proliferation and expansion of metastases.								
DS-1647(G47D)	Oncolytic HSV-1	Glioblastoma	JP	P2	Injection	ActiVec Inc.	-	February 2016: MHLW granted SAKIGAKE designation Investigator Initiated Study is on-going July 2017: MHLW granted Orphan Drug Designation
		The third generation oncolytic herpes simplex virus type 1(HSV-1), genetically-engineered to restrict virus replication to tumor cells. This oncolytic virus therapy is expected equal or better safety and better efficacy profile compare to existing oncolytic virus.						
[fam-] trastuzumab deruxtecan/ DS-8201	Anti-HER2 antibody drug conjugate	Breast cancer (HER2 positive, post T-DM1)	JP/US/EU/Asia	P2	Injection	-	2021	December 2016: FDA granted Fast Track Designation for HER2 positive metastatic breast cancer August 2017: FDA granted Breakthrough Therapy Designation for HER2 positive locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-DM1)
		P3						
		Breast cancer (HER2 positive, vs T-DM1)	JP/US/EU/Asia	P3		-	-	
		Breast cancer (HER2 low)	JP/US/EU/Asia	P3		-	-	
		Gastric cancer (HER2 expressing, post trastuzumab)	JP/Asia	P2		-	2021	March 2018: MHLW granted SAKIGAKE Designation for the treatment of HER2-overexpressing advanced gastric or gastroesophageal junction cancer
		Colorectal cancer	JP/US/EU	P2		-	-	
		Non-small cell lung cancer	JP/US/EU	P2		-	-	
		Breast cancer, urothelial (bladder) cancer	US/EU	P1		Bristol-Myers Squibb	-	Combination with nivolumab
The drug (payload) conjugated through linker to the fully human monoclonal antibody to target HER2, one of the Epidermal Growth Factor Receptor (EGFR) family of proteins. Payload is potent topoisomerase I inhibitor with high membrane permeability. With bystander effect it provides neighbor cell death. Drug-to antibody ratio is 7-8.								
Axicabtagene Ciloleuce/Axi-Cel®	Anti-CD19 CAR-T cells	B Cell Lymphoma	JP	P2	Injection	Kite/Gilead	-	October 2018: MHLW granted Orphan Drug Designation for B-Cell Lymphoma
		Chimeric antigen receptor T (CAR-T), which is a cell therapy directed against CD19, an antigen expressed on the surface of B-cell malignant lymphoma cells.						

Underline: change after FY2018 Q2 Financial Announcement in October 2018

◆ Oncology (Early-stage pipeline products)

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
Milademetan/DS-3032	MDM2 inhibitor	Solid tumors	JP/US	P1	-	-	
		Acute myeloid leukemia	<u>JP/US</u>	P1	-	-	Added a combination cohort with azacitidine (in US)
		Acute myeloid leukemia	US	<u>P1</u>	-	-	Combination with quizartinib
DS-3201	EZH1/2 inhibitor	Adult T-cell leukemia/lymphoma, peripheral T-cell lymphoma	JP	P1	-	-	
		Acute myeloid leukemia , Acute lymphoblastic leukemia	US	P1	-	-	
U3-1402	Anti-HER3 antibody drug conjugate	Breast cancer	JP/US	P1/2	-	-	
		Non-small cell lung cancer	US	P1	-	-	
DS-1001	IDH1 mutant inhibitor	Glioma	JP	P1	-	-	
DS-1205	AXL inhibitor	Non-small cell lung cancer	JP	P1	-	-	Combination with gefitinib
			<u>Asia</u>	P1 prep	-	-	Combination with osimertinib
PLX2853	BRD4 inhibitor	Acute myeloid leukemia, solid tumors	US	P1	-	-	
DS-1062	Anti-TROP2 antibody drug conjugate	Solid tumors (non-small cell lung cancer)	JP/US	P1	-	-	

Underline: change after FY2018 Q2 Financial Announcement in October 2018

◆ Cardiovascular-Metabolics (Late-stage pipeline products)

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
Edoxaban/DU-176b Lixiana (JP) LIXIANA (EU, Asia) SAVAYSA (US)	Factor Xa inhibitor	Atrial fibrillation (AF)	ASCA	<u>Approved</u>	Oral	-	-	<u>December 2018: approved in China</u>
		Venous thromboembolism	ASCA	<u>Approved</u>			-	<u>December 2018: approved in China</u>
		Very elderly patients with non-valvular AF	JP	P3			2021	Additional dosage and formulation for very elderly (80 years and older) AF patients
The once daily oral anti coagulant (Factor Xa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood.								
Prasugrel/CS-747 Effient (US, Asia) Efiect (JP, EU)	Anti-platelet agent	Ischemic stroke	JP	P3	Oral	Ube Industries	2021	Additional indication Additional P3 study started
The oral antiplatelet agent. Prasugrel helps to keep blood platelets from clumping together and developing a blockage in an artery.								
Esaxerenone/CS-3150 Minnebros	MR blocker	Hypertension	JP	<u>Approved</u>	Oral	Exelixis, Inc.	2019	<u>January 2019: approved in Japan</u>
		Diabetic nephropathy	JP	P3			2021	
The agent inhibits aldosterone binding to Mineralocorticoid Receptor (MR) which stimulate the sodium absorption into kidney. This agent is expected to exhibit antihypertensive and organ-protective effect.								

Underline: change after FY2018 Q2 Financial Announcement in October 2018

◆ Cardiovascular-Metabolics (Early-stage pipeline products)

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
DS-1040	TAFIa inhibitor	Acute ischemic stroke, acute pulmonary embolism	JP/US/EU	P1	-	-	
DS-2330	Hyperphosphatemia treatment	Hyperphosphatemia in chronic kidney disease	-	P1	-	-	

Underline: change after FY2018 Q2 Financial Announcement in October 2018

◆ Internal Medicine (Late-stage pipeline products)

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
Mirogabalin/DS-5565 Tarlige (JP)	α ₂ δ ligand	Diabetic peripheral neuropathic pain	JP/Asia	Approved	Oral	-	2018	January 2019: approved in Japan. Indication: Peripheral Neuropathic Pain (PNP)
		Postherpetic neuralgia						
The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.								
Laninamivir/CS-8958 Inavir (JP)	Neuraminidase inhibitor	Influenza	JP	Submitted	Inhalation	-	2019	Additional dosage form, nebulizer formulation July 2018: submitted
The long-acting neuraminidase inhibitor and acts directly on the pulmonary and tracheal sites of infection.								

Underline: change after FY2018 Q2 Financial Announcement in October 2018

◆ Internal Medicine (Early-stage pipeline products)

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
DS-5141	ENA oligonucleotide	Duchenne muscular dystrophy	JP	P1/2	ODTI	-	April 2017: MHLW granted SAKIGAKE Designation April 2018: announced top line result
DS-1211	TNAP inhibitor	Prevention of ectopic calcification diseases	US	P1	-	-	Research collaboration with Sanford Burnham Prebys Medical Discovery Institute

Underline: change after FY2018 Q2 Financial Announcement in October 2018

◆ Vaccines

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
VN-0107/MEDI3250	Live attenuated influenza vaccine	Prevention of seasonal influenza	JP	Submitted	Nasal spray	AstraZeneca/ MedImmune	-	June 2016: submitted by Daiichi Sankyo
The US brand name of this vaccine is FluMist Quadrivalent that is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains.								
VN-0105	DPT-IPV/Hib vaccine	Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib	JP	P3	Injection	Sanofi Pasteur	-	Co-develop with Sanofi K.K.and KDSV
A combination vaccine reconstituting Hib with precipitated and purified pertussis-diphtheria-tetanus-inactivated polio vaccine (Salk vaccine) vaccine launched in Japan, as 1st in the class of pentavalent vaccine (DPT-IPV/Hib).								
VN-0102/JVC-001	Measles-Mumps-Rubella vaccine	Prevention of Measles, Mumps and Rubella	JP	P1/2	Injection	-	-	Continuing development within Daiichi Sankyo is under preparation with the dissolution of Japan Vaccine Company

Underline: change after FY2018 Q2 Financial Announcement in October 2018

◆ Stage-up (major changes from the FY2018 Q2 Financial Announcement in October 2018)

Generic Name/Project Code Number	Class	Target indication	Current region/stage		Remarks
Quizartinib/AC220	FLT3 inhibitor	Acute myeloid leukemia (relapsed/refractory)	US/EU	Submitted	November 2018: submitted in US and EUJapan
[fam-] trastuzumab deruxtecan/ DS-8201	Anti-HER2 antibody drug conjugate	Breast cancer (HER2 low)	JP/US/EU/ Asia	P3	
Milademetan/DS-3032	MDM2 inhibitor	Acute myeloid leukemia	US	P1	Combination with quizartinib
Edoxaban/DU-176b	Factor Xa inhibitor	Atrial fibrillation (AF)	ASCA	Approved	December 2018: approved in China
Lixiana (JP) LIXIANA (EU, Asia) SAVAYSA (US)		Venous thromboembolism	ASCA	Approved	December 2018: approved in China
Esaxerenone/CS-3150 Minnebro	MR blocker	Hypertension	JP	Approved	January 2019: approved in Japan
Mirogabalin/DS-5565 Tarlige	$\alpha_2\delta$ ligand	Peripheral neuropathic pain	JP	Approved	January 2019: approved in Japan

◆ Discontinue (major changes from the FY2018 Q2 Financial Announcement in October 2018)

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
PLX7486	FMS/TRK inhibitor	Solid tumors	US	P1	-	-	Strategic reason
PLX8394	BRAF inhibitor	Solid tumors	US	P1	-	-	Strategic reason
PLX9486	KIT inhibitor	Solid tumors (gastrointestinal stromal tumor)	US	P1	-	-	Strategic reason
PLX51107	BRD4 inhibitor	Acute myeloid leukemia, myelodysplastic syndrome, solid tumor	US	P1	-	-	Strategic reason
DS-1501	Anti-Siglec-15 antibody	Osteoporosis	US	P1	-	-	Strategic reason

◆ Out-licensing

Generic Name/Project Code Number	Class	Target indication	Region / stage when out-licensing		Remarks
DS-6051	NTRK/ROS1 inhibitor	Solid tumors	JP/US	P1	<u>December 2018: out-licensed to AnHeart</u>
<u>PLX7486</u>	<u>FMS/TRK inhibitor</u>	<u>Solid tumors</u>	<u>US</u>	<u>P1</u>	
<u>PLX8394</u>	<u>BRAF inhibitor</u>	<u>Solid tumors</u>	<u>US</u>	<u>P1</u>	
<u>PLX9486</u>	<u>KIT inhibitor</u>	<u>Solid tumors (gastrointestinal stromal tumor)</u>	<u>US</u>	<u>P1</u>	
Laninamivir/CS-8958 Inavir (JP)	Neuraminidase inhibitor	Influenza	US/EU	P2	Out-licensing with Vaxart Inc
DS-2969	GyrB inhibitor	Clostridium difficile infection	US	P1	
DS-1093	HIF-PH inhibitor	Inflammatory bowel disease	EU	P1	Developed until P1 in EU for indication of neurogenic anemia
DS-7080	Angiogenesis inhibitor	Neovascular age-related macular degeneration	US	P1	
<u>DS-1501</u>	<u>Anti-Siglec-15 antibody</u>	<u>Osteoporosis</u>	<u>US</u>	<u>P1</u>	<u>Region for out-licensing: US/EU (other than JP)</u>
DS-1515	PI3K δ inhibitor	Inflammatory disease	-	Pre-clin	
DS-1039	MOA undisclosed (CFTR independent fluid secretion)	Cystic fibrosis	-	Pre-clin	
<u>ASB29609</u>	<u>5-HT5A receptor agonist</u>	<u>Circadian rhythm sleep-wake disorders</u>	-	<u>Pre-clin</u>	

Underline: change after FY2018 Q2 Financial Announcement in October 2018